[Adjuvant immunotherapy with levamisole for malignant glioma].
The long-term therapeutic results in patients with glioblastoma multiforme and malignant astrocytoma were compared between 15 cases of levamisole treated group and 18 cases of control group similar in method and time of treatment to the levamisole treated group. As the result, it was found that the prolongation of life was noted in the levamisole treated group compared with the control. In adult patients, the levamisole treated group survived significantly longer than the control group (p less than 0.05). There is, however, no significant difference of prolongation of the survival time between the levamisole treated (8 cases) and control (8 cases) groups, both which were pretreated by chemoradiotherapy using ACNU and vincristine. This paper refers also to side effects of levamisole.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage; D001932:Brain Neoplasms / Q000628:therapy*; D001973:Bromodeoxyuridine / Q000008:administration & dosage; D002648:Child; D002675:Child, Preschool; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D005909:Glioblastoma / Q000628:therapy*; D006801:Humans; D007978:Levamisole / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D015376:Nimustine; D009607:Nitrosourea Compounds / Q000008:administration & dosage; D014750:Vincristine / Q000008:administration & dosage
D000970:Antineoplastic Agents; D009607:Nitrosourea Compounds; D015376:Nimustine; D007978:Levamisole; D014750:Vincristine; D001973:Bromodeoxyuridine